AIM ImmunoTech Inc. (AIM) is a publicly traded Healthcare sector company. As of July 7, 2026, AIM trades at $0.30 with a market cap of $7.76M and a P/E ratio of -0.03. AIM moved -0.91% today. Year to date, AIM is -76.40%; over the trailing twelve months it is -96.64%. Its 52-week range spans $0.06 to $20.33. Analyst consensus is buy with an average price target of $5.25. Rallies surfaces AIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for AIM, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $0.30 |
| Market Cap | $7.76M |
| P/E Ratio | -0.03 |
| EPS | $-8.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.33 |
| 52-Week Low | $0.06 |
| Volume | 397.48K |
| Avg Volume | 0 |
| Revenue (TTM) | $88.00K |
| Net Income | $-13.96M |
| Gross Margin | 0.00% |
2 analysts cover AIM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.25.